Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes
Van Dyke, Thomas E.
MetadataShow full item record
CitationWang, Chin-Wei, Romain A. Colas, Jesmond Dalli, Hildur H. Arnardottir, Daniel Nguyen, Hatice Hasturk, Nan Chiang, Thomas E. Van Dyke, and Charles N. Serhan. 2015. “Maresin 1 Biosynthesis and Proresolving Anti-Infective Functions with Human-Localized Aggressive Periodontitis Leukocytes.” Edited by B. A. McCormick. Infection and Immunity 84 (3): 658–65. https://doi.org/10.1128/iai.01131-15.
AbstractLocalized aggressive periodontitis (LAP) is a distinct form of early-onset periodontitis linked to periodontal infection with uncontrolled inflammation and leukocyte-mediated tissue destruction. The resolution of inflammation is an active process orchestrated by specialized proresolving lipid mediators (SPMs). Since the level of the Maresin pathway marker 14-hydroxy-docosa-hexaenoic acid (14-HDHA) was lower in activated peripheral blood from LAP patients, we investigated the Maresin 1 (MaR1) biosynthetic pathway in these subjects and its role in regulating phagocyte functions. Macrophages from LAP patients had a lower level of expression of 12-lipoxygenase (similar to 30%) and reduced MaR1 (LAP versus healthy controls [HC], 87.8 +/- 50 pg/10(6) cells versus 239.1 +/- 32 pg/10(6) cells). Phagocytosis by LAP macrophages was reduced similar to 40% compared to that of HC, and killing of periodontal pathogens, including Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, were similarly reduced. LAP neutrophils also displayed slower kinetics (similar to 30%) and decreased maximal phagocytosis (similar to 20% lower) with these pathogens than those of HC. The administration of MaR1 at 1 nM enhanced phagocytosis (31 to 65% increase), intracellular antimicrobial reactive oxygen species production (26 to 71% increase), bacterial killing of these periodontal pathogens (22 to 38% reduction of bacterial titers), and restored impairment of LAP phagocytes. Together, these results suggest that therapeutics targeting the Maresin pathway have clinical utility in treating LAP and other oral diseases associated with infection, inflammation, and altered phagocyte functions.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41483456
- HMS Scholarly Articles